Risperidone
Is It Right for You?
A complete guide to Risperidone — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Risperidone?
Risperidone is a second-generation (atypical) antipsychotic available in oral tablets (0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, and 6 mg), oral solution (1 mg/mL), and as a long-acting injectable formulation (Risperdal Consta). It was among the first atypical antipsychotics to be developed and has an extensive evidence base across schizophrenia, bipolar disorder, and behavioural indications.
Risperidone's distinguishing pharmacological feature is its potent dopamine D2 and serotonin 5-HT2A receptor antagonism, which provides antipsychotic efficacy while reducing the extrapyramidal side effects (EPSEs) associated with older first-generation antipsychotics — though risperidone has a higher propensity for EPSEs and prolactin elevation than many other atypical antipsychotics.
Risperidone is a prescription-only medication in the UK. Initiation and ongoing supervision require specialist psychiatric assessment.
What Conditions Is Risperidone Used For?
Risperidone is indicated for:
treatment of acute psychotic episodes and maintenance treatment to prevent relapse; effective against positive symptoms (hallucinations, delusions, disorganised thinking) and moderately so against negative symptoms
treatment of acute mania and as part of maintenance therapy to prevent mood episode recurrence
short-term management of persistent aggression in Alzheimer's dementia where other interventions have failed and there is a risk of harm (used with caution due to significant risks in elderly patients)
Risperidone manages psychotic and mood symptoms effectively but does not resolve the underlying neurobiological condition. Long-term maintenance therapy is typically required in schizophrenia to prevent relapse. Discontinuation without psychiatric supervision carries a high risk of psychotic relapse.
How Does Risperidone Work?
Risperidone's antipsychotic and mood-stabilising effects arise from its activity at multiple receptor systems:
Dopamine D2 receptor antagonism: Risperidone blocks postsynaptic dopamine D2 receptors in the mesolimbic pathway — the principal mechanism underlying its antipsychotic efficacy against positive symptoms (hallucinations, delusions). D2 blockade in the nigrostriatal pathway produces extrapyramidal side effects; in the tuberoinfundibular pathway, it causes elevation of prolactin. Risperidone has relatively high D2 affinity compared to other atypical antipsychotics, contributing to its higher EPSE and hyperprolactinaemia profile.
Serotonin 5-HT2A receptor antagonism: Risperidone is a potent antagonist at 5-HT2A receptors. Serotonin modulates dopamine release; 5-HT2A blockade in the cortex and limbic system attenuates dopamine release from presynaptic neurons, moderating the D2 blockade in motor pathways (reducing EPSE risk relative to first-generation antipsychotics) and contributing to improvements in negative symptoms, mood, and cognitive function.
Additional receptor activity: Risperidone also antagonises alpha-1 and alpha-2 adrenergic receptors (causing orthostatic hypotension) and histamine H1 receptors (causing sedation and weight gain).
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Can be taken with or without food. Food does not significantly affect absorption.
Take at the same time each day. Consistent dosing supports stable plasma levels. Oral solution can be mixed with water, orange juice, or low-fat milk — not tea or cola.
Do not stop suddenly. Abrupt discontinuation risks psychotic relapse and cholinergic rebound symptoms (nausea, sweating, insomnia). Doses should be tapered under psychiatric supervision.
Elderly patients require significantly lower doses. The pharmacokinetics of risperidone change with age and renal function; elderly patients are more sensitive to sedation, postural hypotension, and EPS effects.
Report any unusual movements. Early signs of extrapyramidal side effects (stiffness, restlessness, involuntary movements) must be reported promptly for dose review.
Side Effects of Risperidone
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Extrapyramidal symptoms (EPS) --- parkinsonism, akathisia (inner restlessness), dystonia; more common with risperidone than with other atypicals, particularly at higher doses
- Hyperprolactinaemia --- sexual dysfunction, menstrual irregularities, galactorrhoea, gynaecomastia, reduced bone density with long-term use
- Weight gain and metabolic effects
- Sedation and fatigue
- Orthostatic hypotension (dizziness on standing)
- Insomnia, anxiety, or agitation
- Nasal congestion
- Tardive dyskinesia (TD) --- potentially irreversible involuntary movements (typically orofacial); risk increases with duration and dose; requires urgent psychiatric review.
- Neuroleptic malignant syndrome (NMS) --- rare but potentially fatal; hyperthermia, severe muscle rigidity, autonomic instability, altered consciousness; requires immediate emergency care.
- Cerebrovascular events (stroke / TIA) --- significantly increased risk in elderly patients with dementia; risperidone carries a black-box warning in this population.
- Prolonged QT interval and ventricular arrhythmias --- monitor ECG in at-risk patients.
- Severe metabolic syndrome --- hyperglycaemia, new-onset diabetes, dyslipidaemia.
Risperidone, like all antipsychotics, is associated with a significantly increased risk of cerebrovascular events (stroke, TIA) and all-cause mortality in elderly patients with dementia-related psychosis. It is licensed in the UK for short-term treatment of persistent aggression in Alzheimer's dementia only — when other interventions have failed — at the lowest effective dose, for the shortest time, with careful benefit-risk discussion documented.
Drug Interactions
Risperidone may interact with other medications, including strong CYP3A4 inhibitors and nephrotoxic agents. Always inform your clinician about all medications you are taking.
significantly reduce risperidone plasma levels; dose adjustments required.
increase risperidone plasma levels; monitor for increased side effects.
risperidone antagonises dopaminergic effects; may worsen Parkinson's disease symptoms; avoid where possible.
no clinically significant interaction.
Important Warnings
Risperidone is associated with increased risk of stroke and death in elderly patients with dementia. It should only be used in this population under specialist supervision, for the shortest possible duration, at the lowest effective dose, with written informed consent from the patient or their representative.
NMS is a rare but life-threatening emergency. Any patient on risperidone developing fever, severe muscle rigidity, sweating, and confusion must receive immediate emergency assessment. Risperidone must be stopped and supportive care initiated.
Long-term antipsychotic use can cause tardive dyskinesia — potentially irreversible involuntary movements. The risk should be discussed with patients before starting treatment and monitored at every review using a standardised assessment.
Weight, BMI, blood pressure, fasting glucose, and fasting lipids must be checked at baseline and monitored at regular intervals (typically at 3 months and annually thereafter) due to the metabolic effects of risperidone.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Risperidone FAQs
Sedation and some behavioural effects may be apparent within days of starting treatment. The full antipsychotic effect on positive symptoms typically emerges over 2–4 weeks, while improvements in negative symptoms and cognition may take longer. Full benefit is often not seen for 6–8 weeks at a therapeutic dose.
Weight gain is a recognised side effect of risperidone, though it is generally less pronounced than with olanzapine or clozapine. Weight and metabolic parameters should be monitored regularly. Dietary advice and exercise support are important adjuncts to management.
Akathisia is an inner feeling of restlessness — a compulsion to move, pace, or fidget — caused by dopamine D2 blockade in the motor system. It is one of the most distressing side effects of antipsychotics and is frequently misidentified as anxiety or worsening of psychiatric symptoms. Report it promptly to your clinician; it can often be managed with dose reduction, beta-blockers, or a change of antipsychotic.
Discontinuing antipsychotic therapy without psychiatric supervision carries a high risk of psychotic relapse, even in patients who have been well for extended periods. Any desire to reduce or stop risperidone should be discussed thoroughly with your psychiatrist, who can advise on gradual, supervised tapering.
Data on risperidone in pregnancy are limited. Antipsychotic therapy during pregnancy must balance the risk of untreated psychosis against potential fetal effects. Neonatal adaptation syndrome has been reported with antipsychotic use in the third trimester. All decisions should be made jointly with a perinatal psychiatrist.